NCT06132893: An ongoing trial by Biohaven Therapeutics Ltd.
This trial is ongoing. It must report results 2 years, 1 month from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06132893 |
|---|---|
| Title | A Phase 2/3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Efficacy, Safety and Tolerability of BHV-7000 in Subjects With Refractory Focal Onset Epilepsy |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 14, 2024 |
| Completion date | Dec. 31, 2026 |
| Required reporting date | Dec. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Nov. 14, 2025 |
| Days late | None |